Export Mendeley
＜journal article＞
Challenge to Cure Lung Cancer by Drug ; Past Present and Future
| Creator | |
|---|---|
| Language | |
| Publisher | |
| Date | |
| Source Title | |
| Vol | |
| Issue | |
| First Page | |
| Last Page | |
| Publication Type | |
| Access Rights | |
| JaLC DOI | |
| Abstract | Development of drug therapy for lung cancer originates in cytotoxic drugs. Following the report which indicate usefulness of cyclophosphamide for lung cancer, many cytotoxic drugs including cisplatin ...and taxanes were developed in the last century. However, their efficacy was modest and cure of metastatic lung cancer used to be an impossible dream. The paradigm shifted in 21st century due to a development of molecular targeted therapy followed by discovery of driver gene mutation. Today, selection of appropriate drug for patient with non-small cell lung cancer (NSCLC) is based on biomarker test including driver gene mutation, resulting in enhancement of therapeutic effects and avoidance of ineffective drugs. In addition, immune check point inhibitor was known to bring patientsʼ long term survival. Before cisplatin, 5-year survival rate of metastatic NSCLC used to be less than 1%. While, our present goal is to achieve longer than 50%. The era to cure lung cancer with drug therapy is just around the corner.show more |
| Table of Contents | 災い転じて福となす：抗癌薬の事始め 毒と薬の境界線：細胞障害性抗癌薬の発展 環境ではない，アイデアだ：ドライバー遺伝子の発見と肺癌薬物療法のバラダイムシフト 我々はどこまで来たのか？ |
Hide fulltext details.
| File | FileType | Size | Views | Description |
|---|---|---|---|---|
p146
|
2.14 MB | 547 |
Details
| PISSN | |
|---|---|
| NCID | |
| Record ID | |
| Peer-Reviewed | |
| Subject Terms | |
| Type | |
| Created Date | 2019.12.18 |
| Modified Date | 2021.03.03 |